List of Excipients in Branded Drug XCOPRI

Xcopri Excipient Strategy and Commercial Opportunities for Cenobamate

Last updated: August 10, 2026

Xcopri is an oral cenobamate tablet for partial-onset seizures in adults. Its excipient platform is conventional, low-cost, and suitable for generic substitution, reformulation, regional manufacturing, and lifecycle extensions. The strongest commercial opportunities are dose-flexible oral products, orally disintegrating tablets, pediatric or dysphagia-friendly presentations, and differentiated combination products. The principal constraints are cenobamate’s titration schedule, serious hypersensitivity risk, drug-interaction profile, and the need to preserve dose uniformity across multiple strengths.

What is Xcopri and how is cenobamate formulated?

Xcopri contains cenobamate, a small-molecule antiseizure medicine developed by SK Biopharmaceuticals and marketed in the United States by SK Life Science. The FDA approved Xcopri in November 2019 for the treatment of partial-onset seizures in adults. The approved product is supplied as immediate-release, film-coated tablets in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg strengths.[1]

The labeled inactive ingredients are:

Component	Function in the Xcopri tablet
Lactose monohydrate	Diluent and bulk carrier
Microcrystalline cellulose	Diluent and dry-compression support
Croscarmellose sodium	Superdisintegrant
Povidone K30	Binder
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-coating polymer
Titanium dioxide	Opacifier and colorant
Talc	Anti-tacking and coating aid
Polyethylene glycol	Plasticizer in the film coat

The core formulation uses a standard direct-compression or wet-granulation excipient architecture. The public label identifies the excipients but does not disclose the quantitative composition, manufacturing process parameters, particle-size specifications, or supplier grades.[1]

What dosage forms does Xcopri use?

Xcopri is an immediate-release tablet. The product is taken once daily and must be initiated at 12.5 mg, followed by gradual dose increases every two weeks. The labeled maintenance range is 200 mg daily, with a maximum recommended dose of 400 mg daily.[1]

The titration schedule creates an important commercial requirement: manufacturers need a complete strength portfolio rather than a single high-dose product. The 12.5 mg and 25 mg tablets are particularly important because they support initiation and dose escalation. A generic or alternative formulation that lacks these strengths would be less clinically interchangeable and commercially less competitive.

What excipient strategy does Xcopri use?

Xcopri uses a low-complexity oral solid dosage strategy. The formulation does not depend on a novel carrier, modified-release polymer, lipid system, or specialized absorption enhancer.

Lactose and microcrystalline cellulose

The combination of lactose monohydrate and microcrystalline cellulose provides tablet mass, compressibility, and mechanical strength. It also gives the manufacturer flexibility to manage the relatively low drug load in the lower strengths.

This combination is commercially attractive because both excipients are widely available and supported by extensive pharmaceutical manufacturing experience. It also creates a potential limitation for patients with lactose intolerance or for companies seeking a lactose-free positioning.

Croscarmellose sodium

Croscarmellose sodium supports rapid tablet breakup after ingestion. For an immediate-release antiseizure product, rapid disintegration is generally more valuable than prolonged release. A generic manufacturer could evaluate alternative superdisintegrants, such as sodium starch glycolate or crospovidone, but the substitution would require comparative development work covering disintegration, dissolution, friability, and stability.

Povidone K30

Povidone K30 functions as a binder and supports granule or tablet integrity. Its presence indicates that mechanical robustness was prioritized across the six-strength product line. A manufacturer seeking a simplified process could examine copovidone or lower-viscosity povidone, although changes in binder level can affect dissolution and tablet hardness.

Magnesium stearate

Magnesium stearate reduces friction during compression and ejection. Its concentration and mixing time are critical because over-lubrication can reduce tablet hardness or slow dissolution. This is a standard scale-up risk rather than a distinctive Xcopri barrier.

Film-coating system

The coating uses polyvinyl alcohol, titanium dioxide, talc, and polyethylene glycol. This is a conventional aqueous film-coating system. It supports appearance, swallowability, product identification, and protection from handling damage.

The coating is unlikely to create a high barrier to generic entry. It may, however, protect product differentiation through color, shape, imprinting, and packaging. Those elements can matter in a multi-strength titration product where medication errors are a commercial and regulatory concern.

What commercial opportunities exist for Xcopri excipients?

The largest opportunity is not a proprietary excipient. It is a better delivery format built around cenobamate’s clinical use pattern.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, swallowing difficulty, or poor adherence to conventional tablets. A formulation could use crospovidone, mannitol, low-substituted hydroxypropyl cellulose, or other rapidly dispersing excipient systems.

The main development risks are:

• Taste masking for cenobamate
• Dose uniformity at the 12.5 mg strength
• Moisture sensitivity
• Mechanical strength during packaging and transport
• Bioequivalence to the immediate-release tablet
• Acceptable disintegration without excessive friability

A low-dose orally disintegrating product could be especially useful during titration, but the commercial case depends on whether the sponsor can secure regulatory substitution or obtain differentiated market positioning.

Lactose-free tablets

The current labeled formulation includes lactose monohydrate. A lactose-free tablet could replace lactose with mannitol, anhydrous dibasic calcium phosphate, additional microcrystalline cellulose, or another suitable diluent.

This change would likely be straightforward from a formulation perspective, but the commercial benefit is narrower than for an orally disintegrating product. Most patients with lactose intolerance can tolerate the small lactose quantities found in many tablets. A lactose-free claim therefore may have limited pricing power unless combined with another advantage.

Smaller tablets and high-dose mini-tablets

The 200 mg and 400 mg daily doses create an opportunity to reduce pill burden. A high-strength tablet or multiparticulate mini-tablet could improve convenience, but it would need to maintain dose uniformity and prevent tablet size from becoming difficult to swallow.

A 400 mg tablet could be commercially attractive if it reduces the number of tablets taken per day. The product would need careful evaluation because higher-strength units can increase the consequence of dosing errors during titration.

Pediatric and geriatric presentations

Xcopri is approved for adults, but pediatric development or off-label use could create demand for liquid, dispersible, or flexible-dose presentations. Liquid formulations would require:

• Suspension stability or true-solution development
• Taste masking
• Preservative selection
• Container-closure compatibility
• Accurate dosing devices
• Control of cenobamate exposure across the dosing range

A liquid formulation could expand administration options but would face greater stability and palatability risks than a tablet.

Combination packaging

The titration schedule supports calendar packs, starter packs, and color-coded strength systems. These are packaging opportunities rather than excipient opportunities, but they can improve initiation accuracy and reduce dispensing errors.

A commercial package could combine:

• 12.5 mg and 25 mg initiation strengths
• 50 mg and 100 mg escalation strengths
• Maintenance strengths up to 200 mg
• Printed titration instructions
• Distinct tablet colors and blister compartments

Such packaging may have more practical value than a marginal tablet-excipient change.

What formulation patents protect Xcopri?

The commercially important IP position is expected to center primarily on cenobamate composition-of-matter rights, use patents, and regulatory exclusivities rather than on the disclosed excipient list.

The public FDA labeling does not disclose a proprietary excipient combination that would, by itself, establish a strong formulation barrier.[1] The named excipients are common pharmaceutical ingredients and are not inherently exclusive to SK Life Science.

How strong is the Xcopri formulation patent estate?

The formulation estate appears less difficult to design around than a product based on a specialized delivery platform. A competitor could potentially use:

• A different diluent
• A different superdisintegrant
• A different binder
• A lactose-free composition
• An orally disintegrating format
• A different coating system
• A different manufacturing process

The central legal question is claim scope. A patent claiming cenobamate itself or a broad therapeutic method can remain relevant even if a competitor changes excipients. A narrow claim tied to specific excipient ratios, particle sizes, dissolution limits, or process conditions would be easier to avoid but could complicate abbreviated approval if the reference product’s formulation is not replicated.

No conclusion about infringement should be drawn from the public ingredient list alone. Patent claims, Orange Book entries, prosecution history, and litigation records must be reviewed separately.

What is the FDA regulatory status of Xcopri?

The FDA approved Xcopri under the New Drug Application pathway. It is an oral, immediate-release tablet for adults with partial-onset seizures.[1]

Cenobamate has no biosimilar pathway because it is a chemically synthesized small molecule. Future competitors would pursue abbreviated new drug applications, subject to applicable patent certifications, exclusivity requirements, and bioequivalence standards.

What bioequivalence issues affect generic cenobamate?

A conventional immediate-release tablet should generally be amenable to comparative bioavailability testing. Key development variables include:

• Cmax and AUC
• Food effect
• Dissolution across pH conditions
• Tablet strength proportionality
• Dose uniformity at low strengths
• Stability under accelerated conditions
• Impact of particle size and polymorphic form
• Interaction between formulation changes and cenobamate exposure

The low-dose 12.5 mg product may present the greatest analytical and content-uniformity challenge. The high-dose products may present the greatest tablet-size and mechanical-strength challenge.

When does Xcopri lose exclusivity?

Xcopri’s effective generic-entry timing depends on the interaction of patents, FDA exclusivity, Paragraph IV litigation, settlement terms, and any regulatory extensions.

Exclusivity element	Relevance to Xcopri
New chemical entity exclusivity	Can delay ANDA approval for the statutory period following FDA approval
Orange Book patents	May trigger Paragraph IV certification and patent litigation
Method-of-use patents	Can restrict labeled uses while permitting possible carve-outs
Pediatric exclusivity	Can add six months if granted
Patent-term extension	Can extend an eligible patent for part of the regulatory review period
Settlement agreements	May establish an agreed generic launch date
ANDA approval	Does not necessarily permit launch if listed patents remain enforceable

The FDA approved Xcopri on November 21, 2019.[1] New chemical entity exclusivity therefore provided an initial period during which the FDA generally could not approve an ANDA referencing cenobamate. Patent expiry and generic launch timing require current review of the FDA Orange Book and litigation docket.

What is the Orange Book status of Xcopri?

The Orange Book is the controlling FDA source for listed patents and exclusivity information. Xcopri should be evaluated by reviewing:

1. The current Xcopri NDA listing.
2. Patent numbers and expiration dates.
3. Any pediatric exclusivity notation.
4. Whether listed patents cover the active ingredient, product formulation, or method of use.
5. Whether patents have been removed, delisted, or added.
6. Whether an ANDA applicant has submitted a Paragraph IV certification.

The Orange Book listing is dynamic. Patent dates in secondary databases can differ from the FDA record because of patent-term adjustment, patent-term extension, pediatric exclusivity, statutory disclaimers, or later corrections.[2]

Which companies are challenging Xcopri?

Publicly identifiable generic challenges should be confirmed through current FDA Orange Book data, Paragraph IV notices, district court complaints, and ANDA litigation records. The public label alone does not establish the identity of challengers or the status of litigation.

A commercial diligence review should distinguish among:

• An ANDA filing
• A Paragraph IV notice
• A patent-infringement complaint
• A settlement agreement
• Tentative FDA approval
• Final FDA approval
• Commercial launch

These events have different implications. A Paragraph IV filing can create litigation but does not establish that a generic will launch. A settlement can produce an agreed entry date that is earlier than patent expiry. A final approval remains subject to patent rights and settlement restrictions.

What generic entry risks exist for Xcopri?

Generic entry risk is moderate from a formulation perspective and potentially higher from a market perspective if multiple manufacturers target the product after core patent barriers weaken.

The principal risks are:

• Multiple ANDA applicants pursuing the same immediate-release tablet.
• Low-cost excipient substitution.
• Limited technical differentiation among generic tablets.
• Rapid price erosion after multiple approvals.
• Competition across all titration strengths.
• Substitution pressure from pharmacy benefit managers.
• Alternative antiseizure medicines competing for the same patient population.

The main barrier is likely the cenobamate patent and regulatory exclusivity position, not the conventional excipient system. A generic manufacturer that successfully avoids formulation claims could still face composition-of-matter or method-of-use patents.

How does Xcopri compare with competing antiseizure products?

Product	Active ingredient	Formulation opportunity	Biosimilar risk	Generic risk
Xcopri	Cenobamate	ODT, liquid, lactose-free, titration packs	None	ANDA-based
Briviact	Brivaracetam	Oral solution and tablet differentiation	None	ANDA-based
Vimpat	Lacosamide	Tablet, solution, injection	None	ANDA-based
Epidiolex	Cannabidiol	Oral solution and formulation complexity	None	Small-molecule regulatory pathway
Fintepla	Fenfluramine	Oral solution and dosing-device integration	None	Small-molecule regulatory pathway

Xcopri’s strongest product differentiation is clinical positioning and titration management rather than excipient sophistication. Briviact and Vimpat have broader dosage-form histories, while Epidiolex and Fintepla rely more heavily on liquid-product execution.

What licensing and partnering opportunities exist?

Potential partnering targets include:

• Regional commercialization rights
• Generic or authorized-generic supply
• Orally disintegrating or pediatric formulations
• Contract manufacturing of multiple tablet strengths
• Specialty pharmacy packaging
• Taste-masking technology
• High-speed analytical testing for low-dose tablets
• Dose-compliance packaging

A formulation license would have greater value if it covers a clinically useful delivery advantage, such as rapid disintegration, improved swallowing, lower pill burden, or flexible dosing. A simple substitution of lactose or magnesium stearate would likely have limited standalone licensing value because the ingredients are commodity materials and design-around options are extensive.

What is the revenue exposure to Xcopri patent expiry?

Xcopri revenue is exposed to generic entry through both price erosion and substitution. The impact depends on:

• Net sales before launch
• Number of approved ANDAs
• Timing of first generic entry
• Whether the first entrant has 180-day exclusivity
• Payer substitution policy
• Persistence of cenobamate prescribing
• Availability of authorized generic supply
• Continued use of higher-strength tablets

The best commercial defense is usually a combination of patent protection, clinical evidence, adherence support, specialty distribution, and differentiated dosage forms. Excipient changes alone are unlikely to preserve branded pricing after broad generic entry.

Key Takeaways

• Xcopri is an immediate-release cenobamate tablet with six strengths from 12.5 mg to 200 mg.
• Its disclosed excipient system is conventional: lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and a standard film coat.
• The formulation itself appears relatively design-around friendly.
• The highest-value opportunities are orally disintegrating tablets, pediatric or dysphagia-friendly products, lactose-free tablets, high-strength tablets, and titration packaging.
• Cenobamate has no biosimilar risk because it is a small molecule.
• Generic entry depends primarily on composition-of-matter, method-of-use, Orange Book, exclusivity, and litigation developments rather than on the disclosed excipients.
• Current Orange Book and court-record review is required to establish definitive patent expiration dates, Paragraph IV activity, challengers, and settlement-based entry dates.

FAQs

Can Xcopri be reformulated without lactose?

Yes. Lactose monohydrate could potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent, subject to development and regulatory requirements.

Is an Xcopri orally disintegrating tablet commercially attractive?

Potentially. The strongest target populations are patients with dysphagia, poor tablet adherence, or difficulty managing the titration schedule. Taste masking and dose uniformity would be central development issues.

Does Xcopri have biosimilar competition?

No. Cenobamate is a chemically synthesized small molecule. Competitors would use the generic-drug pathway rather than the biosimilar pathway.

Which Xcopri strength is most important for formulation development?

The 12.5 mg strength is critical for treatment initiation and presents the greatest low-dose content-uniformity challenge. The 200 mg strength is important for maintenance therapy and pill-burden reduction.

Are Xcopri’s excipients likely to block generic approval?

Usually not by themselves. The listed excipients are widely used and can generally be replaced or adjusted if the resulting product meets bioequivalence, quality, stability, and labeling requirements. Patent claims covering cenobamate or its use may remain the more significant barrier.

References

1. U.S. Food and Drug Administration. (2019). Xcopri (cenobamate) tablets, for oral use: Prescribing information. SK Life Science, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Approved drug product labeling and regulatory information for cenobamate. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. SK Life Science, Inc. (2024). Xcopri product information. https://www.xcopri.com/